



Collaborative Care in Myelofibrosis

Clinical Brief #3: Treatment Options – Comparison of Agents

References

Tweet 2

Gerds AT, Harrison C, Kiladjian J-J, et al. S167: Efficacy and safety of luspatercept for the treatment of anemia in patients with myelofibrosis: results from the Ace-536-Mf-001 study. *HemaSphere*. 2023;7:e0882611. doi:10.1097/01.Hs9.0000967580.08826.11

Harrison CN, Vannucchi AM, Platzbecker U, et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. *Lancet Haematol*. 2018;5(2):e73-e81. doi:10.1016/S2352-3026(17)30237-5

Mascarenhas J, Hoffman R, Talpaz M, et al. Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial. *JAMA Oncol*. 2018;4(5):652-659. doi:10.1001/jamaoncol.2017.5818

Mesa R, Harrison C, Oh ST, et al. Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis. *Leukemia*. 2022;36(9):2261-2268. doi:10.1038/s41375-022-01637-7

Oh ST, Mesa RA, Harrison CN, et al. Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis. *Blood Adv*. 2023;010151. doi:10.1182/bloodadvances.2023010151

Verstovsek S, Gerds AT, Vannucchi AM, et al. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. *Lancet*. 2023;401(10373):269-280. doi:10.1016/S0140-6736(22)02036-0

Additional References

Tremblay D, Mesa R. Momelotinib for the treatment of myelofibrosis with anemia. *Future Oncol*. 2022;18(20):2559-2571. doi:10.2217/fon-2022-0276

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Myeloproliferative Neoplasms (v2.2023). Updated August 29, 2023. Accessed August 29, 2023. https://www.nccn.org/professionals/physician_gls/pdf/mpn.pdf

Chifotides HT, Bose P, Verstovsek S. Momelotinib: an emerging treatment for myelofibrosis patients with anemia. *J Hematol Oncol*. 2022;15(1):7. doi:10.1186/s13045-021-01157-4

Fenaux P, Kiladjian JJ, Platzbecker U. Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis. *Blood*. 2019;133(8):790-794. doi:10.1182/blood-2018-11-876888

Verstovsek S, Mesa R, Gupta V, et al. Mometotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials. *Blood Adv.* 2023;7(14):3582-3591. doi:10.1182/bloodadvances.2022009311

Abdelrahman RA, Begna KH, Al-Kali A, et al. Mometotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis. *Br J Haematol.* 2015;169(1):77-80. doi:10.1111/bjh.13262

Masarova L, Verstovsek S, Palandri F, et al. P1057: Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosis. *HemaSphere.* 2023;7(S3):e1863563. doi:10.1097/01.Hs9.0000971124.18635.63

Glossary

AE, adverse event
BAT, best available therapy
BID, twice daily
BMP6, bone morphogenetic protein 6
CI, confidence interval
DIPSS, Dynamic International Prognostic Scoring System
ESA, erythropoiesis-stimulating agent
Hgb, hemoglobin
HR, hazard ratio
i, inhibitor
IL, interleukin
Int, intermediate
JAK, Janus kinase
m, median
MF, myelofibrosis
MMB, momelotinib
NE, not estimable
OR, odds ratio
OS, overall survival
Plt, platelets
RUX, ruxolitinib
SOC, standard of care
SVR35, spleen volume reduction $\geq 35\%$
TD, transfusion dependent
TE-PN, treatment-emergent peripheral neuropathy
Tf, transferrin
TI, transfusion independence
TSS50, total symptom score reduction $\geq 50\%$
w/, with
yo, year old